Prostate Cell News Volume 17.12 | Jul 10 2026

    0
    28






    2026-07-10 | PCN 17.12


    Prostate Cell News by STEMCELL Technologies
    Vol. 17.12 – 10 July, 2026
    TOP STORY

    A Ligandable PNT Domain Establishes ERG As a Directly Targetable Oncogenic Driver in Prostate Cancer

    Researchers demonstrated continued dependency on ERG in metastatic prostate cancer and identified a druggable pocket within its N-terminal Pointed (PNT) domain.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article
    Two cartoon scientists talking animatedly to each other to represent leaders in scientific communication
    PUBLICATIONSListed by the impact factor of the journal

    Butyrylated PGAM5-Triggered and GSH-Responsive Cysteine Polymer Nanoparticles for CBL0137 Delivery to Enhance Necroptosis in Prostate Cancer

    Scientists utilized a cysteine-based, glutathione (GSH)-responsive polymer to deliver antitumor agent CBL0137. Exploiting high GSH levels in prostate cancer cells, the resulting CBL0137-loaded nanoparticles achieved targeted and efficient intracellular delivery and enhanced tumor-killing efficacy.
    [Advanced Healthcare Materials]

    Abstract

    Lactate-Induced H3K4me3 Histone Mark Promotes PLOD1-Driven Prostate Cancer Invasion

    Investigators showed that the lactic acid-induced increase in succinate levels affects the activating H3K4me3 methylation mark in prostate cancer cells, promoting a pro-invasive phenotype.
    [Cell Death & Disease]

    Abstract

    Functional and Omics-Based Rationale for the Induction of BRCAness by Androgen Receptor Pathway Inhibitors to Sensitize Prostate Cancer to PARP Inhibition, Regardless of HRR Status

    Researchers assessed poly (ADP‒ribose) polymerase (PARP) inhibitors alone and with androgen receptor pathway inhibitors in prostate cancer cell lines, metastatic patient-derived organoids, and LN-metastatic tissue slice cultures.
    [British Journal of Cancer]

    Full Article

    SETDB1-Mediated Repression of RhoB Promotes EMT and Metastatic Progression in Prostate Cancer

    Scientists identified SET domain bifurcated 1 (SETDB1) as a key regulator of epithelial–mesenchymal transition (EMT) and metastasis through direct repression of RhoB, the small GTPase. SETDB1 is genomically amplified and transcriptionally upregulated in metastatic CRPC.
    [Oncogene]

    Full Article

    Total Flavonoids from Ageratum conyzoides Synergize with Docetaxel to Induce Ferroptosis in Prostate Cancer Cells via the NRF2/SLC7A11/GPX4 Signaling Pathway

    The authors investigated whether the combined treatment of total flavonoids from Ageratum conyzoides and docetaxel (DTX) can enhance the antitumor effect of DTX on prostate cancer cells by regulating the NRF2/SLC7A11/GPX4 signaling axis and inducing mitochondria-related ferroptosis.
    [Scientific Reports]

    Abstract
    REVIEWS

    Neoadjuvant Intraprostatic Immunotherapy for High-Risk Localized Prostate Cancer

    Novel immunotherapy approaches such as T cell-engager therapies, CD40 agonists, and HSV-TK gene therapy have shown early promise for the treatment of prostate cancer.
    [Nature Reviews Urology]

    Abstract
    INDUSTRY AND POLICY NEWS

    BjöRn Gysell Is Donating to Research into Future Treatments for Prostate Cancer

    A prostate cancer research initiative in Sweden has been made possible by a donation from Björn Gysell. The investment will enable Karolinska Institutet’s research environment in prostate cancer to develop the next generation diagnostics and therapies using AI, genomics and precision medicine.
    [Karolinska Institutet]

    Press Release

    NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

    NeoGenomics, Inc. announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the US FDA for patients with prostate adenocarcinoma.
    [NeoGenomics, Inc.]

    Press Release

    Blue Earth Therapeutics Announces First Participant Dosed in Phase I Clinical Trial Investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in Metastatic Castration-Resistant Prostate Cancer

    Blue Earth Therapeutics and University College London announced initiation of a Phase I clinical trial evaluating Actinium (225Ac) rhPSMA-10.1 Injection, an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical for the treatment of patients within clinical trials in metastatic CRPC.
    [Blue Earth Therapeutics (BioSpace)]

    Press Release
    FEATURED EVENT

    ISEH 55th Annual Scientific Meeting

    August 27-30, 2026
    Frankfurt, Germany

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Immunotherapy in Prostate Cancer

    University of Louisville – Louisville, Kentucky, United States

    Postdoctoral Fellow – Cancer Biology

    Henry Ford Health System – Detroit, Michigan, United States

    Postdoctoral Fellow – Cancer Prevention Fellowship Program

    CICF International, Inc. – Maryland, United States

    Postdoctoral Program – Integrated Science Lab

    Umeå University – Umeå, Sweden

    Postdoctoral Fellow/Staff Scientist – Prostate Cancer

    City of Hope – Duarte, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2